# BriaCell Therapeutics

Source: https://onco.cc/companies/briacell/  
OnCo record `briacell` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BriaCell Therapeutics is a listed company developing off-the-shelf immunotherapies made from cancer cells grown in the laboratory. Its lead treatment, Bria-IMT, is in a phase 3 trial in metastatic breast cancer, and a related platform, Bria-OTS, is in an earlier trial.

## Summary

BriaCell Therapeutics Corp. describes itself as a clinical-stage immuno-oncology company, with a corporate office in West Vancouver, British Columbia, and a United States office in Philadelphia; it is listed on Nasdaq (BCTX) and the Toronto Stock Exchange (BCT). Its lead candidate Bria-IMT is described by the company as a patented, off-the-shelf, cell-based targeted immunotherapy, given with an immune checkpoint inhibitor in a pivotal phase 3 study in metastatic breast cancer; the company states that the FDA granted it Fast Track status. That study, NCT06072612 (BRIA-ABC), compares the Bria-IMT regimen with a checkpoint inhibitor against treatment of the physician's choice. Bria-OTS is a platform of personalised off-the-shelf cell-based immunotherapies in a phase 1/2 study, initially in breast cancer, with prostate cancer named as the next indication. In fiscal year 2026 NCI awarded the company USD 947,870 under SBIR Phase II grant 5R44CA281555-03 for an off-the-shelf tumour cell vaccine with HLA-matching alleles for advanced metastatic prostate cancer.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: BriaCell Therapeutics Corp; BriaCell Therapeutics Corporation; BriaCell
- HQ: West Vancouver, BC
- Type: biotech
- Website: https://briacell.com/
- Ticker: BCTX

## Notes

- Offices, listings, pipeline and the Fast Track statement read on briacell.com, and the award on NIH RePORTER, on 4 November 2026. The Fast Track statement is the company's; the FDA does not publish Fast Track grants.

## Sources

- Official website: https://briacell.com/
- NIH RePORTER: award 5R44CA281555-03: https://reporter.nih.gov/project-details/11398997
- ClinicalTrials.gov: BRIA-ABC phase 3 trial (NCT06072612): https://clinicaltrials.gov/study/NCT06072612

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- drugs: [Bria-IMT](https://onco.cc/drugs/bria-imt/), [Bria-OTS](https://onco.cc/drugs/bria-ots/)
- trials: [Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.](https://onco.cc/trials/nct06072612/)

---
JSON: https://onco.cc/api/v1/entities/briacell.json